Australia's largest stock trading and investment forum Australia's #1 stock forum

UNS

Click for more information

0.00%

0.5¢ unilife corporation

Investor Relations, page-12

First 12 Last

Share
Profile

Follow
wolfofasx

710 Posts.

96

10/11/16

23:48

Post #: 20533898
Share

Originally posted by tralfaz ↑

I highly doubt that Orbimed is going to give them much of anything going forward. This group has now gotten $85 million to work with in less than 12 months and have managed to whittle that down to $18MM as of the last call. They are due another $5MM in January so you're looking at $90MM in a year's time. How much of that will be left? This of course doesn't include any receipts from customers. Although the A/R amount wasn't significant. They also didn't have pay any interest to Orbimed for a cost savings of a couple million. After 3 years of working with MedImmune where are they? Shouldn't they be supplying them with more than samples at this point? Reminds of a song where the singer says, "New verse, same as the first".

Expand

If you look at tranikolumab clinical trials, there is one that looks like it could be a WI because it said 420mg with one injection and that couldn't be done with a syringe. But don't quote me I think it was in the recruiting stage so probably next year

UNS Price at posting: 5.1¢ Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

ZNC

Zenith's sale of Develin Creek delivers $975K cash, with shares up 13%

COD

Coda Minerals (ASX:COD) enters rights issue to further exploration in South Australia

HAS

Hastings progressing Yangibana to production with lower costs

ACW

Actinogen Medical ramps up Alzheimer’s treatment trials, targeting fast-track global approvals

The iron ore comeback: Can it last?

There are more pages in this discussion • 23 more messages in this thread...

First 12 Last

Add UNS (ASX) to my watchlist